Drugs / 225Ac-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04225910 | Jan 2020 → Jun 2021 | prostate carcinoma | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-05-20 | Telix Pharmaceuticals (Innovations) Pty Limited | Results Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer telixpharma.com ↗
Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable characteristics for use with alpha emitting agents. |
| 2024-04-09 | Fusion Pharmaceuticals Inc. | Results Preliminary efficacy and safety results from the TATCIST trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer fusionpharma.com ↗
PSA50 was achieved in 10/20 participants (50%), regardless of prior Lu treatment (Figure 4) |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225910 ↗ |
| Route | Intravenous | “The drug will be administered by vein injection.” NCT04225910 ↗ |